API maker Hovione moves into particle design

Portuguese API maker Hovione has invested in crystal design and particle size reduction to the nanoscale size and amorphose solid dispersion so it can offer those capabilities for the lab or commercial scale-up. The company tells in-PharmaTechnologist that it was hearing from customers that they needed the capability to handle "highly potent compounds." The publication points out that Hovione has been putting attention on solubility solutions. Last year, it struck a deal with Particle Sciences ($PSI) that allowed it to offer scale-up manufacturing services for solubilization processes developed by PSI. Story | More

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.